Portal de Periódicos da CAPES

The shy Angeli and his elusive creature: the HNO route to vasodilation

2009; American Physical Society; Volume: 296; Issue: 5 Linguagem: Inglês

10.1152/ajpheart.00243.2009

1522-1539

Nazareno Paolocci, David A. Wink,

Receptor Mechanisms and Signaling

EDITORIAL FOCUSThe shy Angeli and his elusive creature: the HNO route to vasodilationNazareno Paolocci and David A. WinkNazareno Paolocci and David A. WinkPublished Online:01 May 2009https://doi.org/10.1152/ajpheart.00243.2009This is the final version - click for previous versionMoreFiguresReferencesRelatedInformationSectionsGRANTSAUTHOR NOTESPDF (118 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat what we now call Angeli's salt (AS) was discovered more than a century ago by the Italian chemist Angelo Angeli (Fig. 1) . He found that "salts of nitroxylaminic acid are readily resolved into the corresponding nitrites and the unsaturated residue nitroxyl" (HNO), proposing their use as suppliers of HNO (3). However, by analogy with the genial but very reclusive personality of the discoverer (17), the physiological properties of HNO didn't draw too much attention until early 1990s. In their seminal work, Fukuto and colleagues (19) reported that HNO elicits vasorelaxation in both the rabbit aorta and bovine intrapulmonary artery by a soluble guanylate cyclase (sGC)- dependent pathway. Later, it was evident that the thiol-donating agent l-cysteine can discriminate the vasodilatative profile of HNO from that of nitric oxide (NO·) or nitrosothiols: AS/HNO action can be blocked by this agent, whereas the NO· effect is potentiated (36). In combination with the suggestion that NO· is the only species able to directly activate sGC (9), these data led to the conclusion that HNO-induced vasorelaxation is due to its intracellular conversion to NO· with subsequent activation of sGC. For several years, this idea has relegated HNO to a mere precursor of the presence and biological activity of NO·, de facto negating to HNO its own right to exist.Fig. 1.Angelo Angeli (1864–1931) in his laboratory. [Courtesy of Dr. Marco Fontana and Prof. Maria Grazia Costa (Dipartimento di Chimica Organica, University of Florence, Florence, Italy)].Download figureDownload PowerPointRecent thorough reevaluation of the chemical properties and reactivity of HNO has definitely proved that this molecule is distinct from NO· (28, 33) and other reactive nitrogen species (RNS) (24, 29). Likewise, the use of HNO donors is delineating biological effects that are unique and different from those of NO·-donating compounds, NO· oxidized products, and other ROS/RNS (ONOO−, NO2, or N2O3). This is particularly true in the cardiovascular system, where HNO action is often "orthogonal" to that of NO·/organic nitrates (27, 42) despite some shared features. As a matter of fact, the in vivo infusion of AS/HNO leads to increased inotropy in normal and failing in vivo hearts (34, 35), whereas NO·/organic nitrates are negative or neutral. In vitro vasodilation from AS/HNO doesn't lead to tolerance (23), in stark contrast to the organic nitrate glyceryl trinitrate. Similarly to exogenous NO·, however, when given before ischemia HNO protects the heart against reperfusion damage (32). Furthermore, HNO, like NO·, exerts antiaggregating effects on platelets (5, 21). All this evidence concurs in praising HNO donors as a possible new attractive avenue to treat decompensated hearts and vascular dysfunction. Nevertheless, by and large HNO per se remains an enigma, as "elusive" and "shy" as the scientist who first synthesized the white and soft powder that donates it (26). First and foremost, it is still undetermined whether this chemical entity is set to remain a bench "oddity" (or a pharmacological tool) or if it will finally reveal itself as an endogenous, physiological mediator. Over the last decade, the possible generation of HNO in vivo has been suggested to derive from 1) the direct oxidation of NG-hydroxy-l-arginine, which is an intermediate in the enzymatic conversion of l-arginine to NO· (19); 2) direct reduction of NO· via ubiquinol, cytochrome c, MnSOD, and xanthine oxidase (20, 37); 3) decomposition of nitrosothiols (44); 4) NO· synthase (NOS) in the absence of tetrahydrobiopterin (1); and 5) heme protein-mediated peroxidation of hydroxylamine (11). No definitive proof has been attained yet, and tracking down HNO footprints in vitro and in vivo remains a major current challenge for physicists and biochemists. In theory, HNO should elude spin trapping because, unlike NO·, it is not a radical. However, deoxymyoglobin and metmyoglobin can trap free HNO to form a stable adduct, HNO-myoglobin, or myoglobin-NO (12, 14), and, more recently, selective detection of HNO in solution has been achieved by reductive nitrosylation in xerogel films (10). Still, in physiological buffers, HNO rapidly disappears via dimerization to hyponitrous acid followed by dehydration and the formation of N2O, which, however, doesn't relax vascular beds (19). Alternatively, HNO may evanesce after its fast reaction with thiols (20, 33), and likely this may serve as a HNO signature. As a matter of fact, in vitro HNO reaction with GSH generates sulfinamide and GSSG (12). Whether this is an amenable tool to detect HNO in vivo is currently unclear.Elucidation of the HNO mechanism of action and its associated signaling in the cardiovascular system are other pending issues. In the heart, HNO positive inotropy/lusitropy stems from its ability to interact with thiols, likely cysteines, located in key structures of both the sarcoplasmic reticulum (SR) (6, 18, 38) and myofilaments (8). In this context, HNO enhances Ca2+ cycling and the sensitivity of contractile/regulatory proteins to Ca2+, fully independently from cGMP/PKG and cAMP/PKA (38). Conversely, in the vasculature, the HNO route to vasodilation appears to be more complex, raising several major questions. Are the mechanistic underpins of HNO-induced dilation always similar to those of NO·/organic nitrates? Does HNO impact the same messengers and channels in different vascular beds? Finally, if the HNO vasorelaxant action differs substantially from that of NO·, is HNO vicarious in diseased situations where NO·-dependent endothelial function is impaired? If so, how this happens? In in vitro large conduit vessels, HNO-induced vasorelaxation is accompanied by cGMP accumulation (13, 19, 23, 40). Yet, the direct intravenous infusion of AS (35) or the other HNO donor isopropylamine NONOate (27) into large mammals does not appreciably rise systemic levels of cGMP. There are many possibility to explain this apparent discrepancy, including the presence of adventitious oxidants in in vitro preparations (possibly converting HNO to NO·), the possible in situ compartmentalization of cGMP levels, the dose of HNO donors employed in vivo versus in vitro studies, and, finally, the sensitivity of the cGMP detection methods employed in vivo. This observation, however, combined with in vivo evidence that HNO donors may affect more markedly venous capacitance than arterial resistance (35), calls for different mechanisms and/or sensitivity to HNO in these systemic vascular compartments. It is tempting to speculate that HNO may affect the compartment side through cGMP signaling, whereas it may lower peripheral arterial resistance by releasing the potent vasorelaxant CGRP. Indeed, CGRP per se does not affect venous capacitance because preload is not reduced by CGRP in vivo (25). Thus, sGC/cGMP signaling may not be the only route followed by HNO to induce vasorelaxation in large conduit arterial compartments. This hypothesis is supported by data obtained in coronary arteries showing that the use of the CGRP antagonist CGRP(8–37) significantly blunted HNO-evoked coronary relaxation (15). Considering that 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) abolished the response to AS/HNO, yet CGRP receptor and ATP-sensitive K+ (KATP) channel blockade only suppressed the maximal effect, it seems plausible that CGRP release is dependent on sGC activation. Likewise, the fact that glibenclamide, in part, inhibited the AS/HNO vasodilatory response makes possible that KATP channel activation occurs subsequent to CGRP release. Overall, these mechanistic intricacies unravel a complex interplay of possible mediators of the HNO vascular response that requires further investigation. The role of HNO in the modulation of the tone of resistance vessels is even more complex. In contrast to NO·, which is known to activate Ca2+-activated K+ (KCa) channels (30), Irvine and colleagues (22) have shown that HNO instead targets voltage-gated K+ (Kv) channels, leading to vascular smooth muscle cell hyperpolarization that, at least in part, is sGC/cGMP dependent. When coupled with the possibility of NOS-independent generation of HNO (4, 20, 44), this finding has raised the interesting possibility that HNO may act as an endothelium-derived hyperpolarization factor (EDHF).This HNO-EDHF hypothesis is in part the subject of the contribution by Favaloro and Kemp-Harper in the current issue of the American Journal of Physiology-Heart and Circulatory Physiology (16) that complements other in press observations made by this group on the same topic (2). Here, the authors compared the vasorelaxation mechanisms of HNO and NO· in rat resistance vessels. They evaluated the ability of AS/HNO (0.1 nM–10 μM) and an aqueous solution of authentic NO· gas (0.1 nM–1 μM) to hyperpolarize rat mesenteric arteries and to repolarize them after contraction and depolarization with methoxamine. They found that the endothelium-independent vasorelaxation and repolarization by AS/HNO were attenuated by l-cysteine, 4-aminopyridine (4-AP), and ODQ. Conversely, NO·-mediated repolarization was resistant to both ODQ and 4-AP, suggesting different pathways for HNO signaling in this vascular bed. These findings confirm the redox-sensitive nature of HNO vasorelaxation (22, 36) and the involvement of Kv channels in HNO-induced repolarization, which is mostly sGC/cGMP dependent. The possibility of NO-independent Kv channel activation is supported by the observation that the direct sGC stimulator YC-1 also activated these channels (although more potently than HNO) in a 4-AP-sensitive manner. In contrast, glibenclamide and large-conductance KCa/intermediate-conductance KCa channel inhibitor charybdotoxin were unable to abolish HNO-induced repolarization. Thus, one major conclusion of the present report is that in resistance arteries, in the same concentration range, HNO action is mechanistically and quantitatively distinct from that of pure NO·. HNO donated by AS is more potent than NO in eliciting vascular repolarization (48% vs. 14%), and nitrite has no part in the AS action. Moreover, these data hint at the concrete possibility that in this vascular bed HNO activates sGC directly with an as-yet-undefined mechanism. Indeed, sGC inhibition by ODQ more markedly blunts HNO than NO· action. The authors excluded the extracellular conversion of HNO to NO· using the metal chelator EDTA and the NO· scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide, although the possibility of intracellular oxidation still persists. In another study (2), the authors made another important observation, identifying a putative contribution of HNO to ACh-mediated vasorelaxation in mouse mesenteric arteries. They found that in these vessels the response to ACh was in part inhibited by l-cysteine or 4-AP (up to a 25-fold reduction in potency). ACh-induced hyperpolarization in these vessels was reduced by ∼45% with 4-AP, and this response was further attenuated by combining 4-AP with the NOS inhibitor N-nitro-l-arginine methyl ester (l-NAME). In this setting, vasorelaxation induced by the NO· donor diethylamine NONOate was unchanged by 4-AP. Therefore, the authors concluded that endogenously generated HNO may contribute to endothelium-dependent hyperpolarization evoked by ACh in mouse mesenteric arteries. However, they also highlighted the fact that NO· may take some part in mouse mesenteric artery vascular smooth muscle hyperpolarization as l-NAME combined with 4-AP virtually abolished ACh effects. Thus, HNO and NO· vasorelaxation may complement each other in resistance vessels, but the lack of physical and/or biochemical evidence for in situ HNO production warrants further studies.Several major considerations and practical implications for the cardiovascular system follow from these studies. Given its peculiar profile, exogenous (or endogenous) HNO may not only complement NO· signaling but also be vicarious when the latter is impaired. This hypothesis is based on the following observations. ROS may trap and neutralize NO·. Vascular smooth muscle typifies this situation as it has multiple sources of ROS generation and many ways for redox-based mechanisms to negatively or positively affect vascular function (43). However, HNO has very different chemical properties than ROS and NO·, which involve radical chemistry (33). HNO would rather act as an electrophil than participate in the propagation of this chemistry (28, 33, 42). This view is supported by the fact that HNO vasorelaxing properties appear preserved in in vivo heart failure (34), where increased oxidative stress is certainly present. Furthermore, loss of nitrovasodilator responsiveness (i.e., vascular tolerance) has been associated with increased vascular superoxide production (31). This is not the case with AS/HNO, both in vivo (35) and in vitro (23). Since some of these outcomes may also be dose dependent, further studies are needed to fully compare HNO responses in normal versus redox-altered vascular tissue and to dissect out the complex network of reactions likely going on between HNO and other ROS/RNS in the vasculature. Finally, HNO from AS has some similarities with nitrite/nitrate (35), which have long been used as unloading tools for the failing heart. In certain vessels, such as the resistance ones, HNO appears to be even more potent than nitrite (22). In the end, Angeli created for us a compound that generates two substances: nitrite and HNO. Both of them may provide alternative to traditional nitrosovasodilators in diseased conditions. Under hypoxia, nitrite can be converted to NO·, providing a redox buffer for the consequences of lack of O2 (7). Conversely, under oxidative stress conditions, NO· is consumed through radical interactions with ROS, leading to decreased bioavailability. In stark contrast, HNO does not readily interact with these radicals. Thus, its chemistry, cardiotropic action, and vasodilatory profile make this molecule (and its donors) almost an ideal pharmacological tool to treat cardiovascular conditions in which pump failure, endothelial dysfunction, and oxidative stress concur.Angeli was nominated nine times for the Nobel Prize by chemists all over Europe (17). Yet, his reluctance to attend congresses, give lectures, and publish his studies (still lying on his chest of drawers for the most part) very likely precluded the full recognition of his creativity and innovative contributions. He expanded our knowledge on pyrrole and indolic compounds, discovering the analogies of behaviour of the para- and ortho-derivatives of benzene. His work on azoxy compounds led him to demonstrate their asymmetric structure and the possibility of obtaining isomers. Angeli also pioneered studies on "constitution and olfactory function," correlating this sensing ability to oxidative reactions. He died in Florence in an anonymous hotel room where he lived in for many years (17). While HNO has been found already in space as a gas (39), we hope that one day this molecule will also be discovered in our bodies. On that day, Angeli's creature, HNO, will finally leave its niche in the kingdom of chemistry and pharmacology to enter the realm of physiology and perhaps pathobiology (37, 41).GRANTSThe present work was supported by National Heart, Lung, and Blood Institute Grant RO1 HL-075265 (to N. Paolocci).The authors gratefully acknowledge Dr. Marco Fontani for providing bibliographical material about Angelo Angeli and discussing details concerning the chemist's life and work.AUTHOR NOTESAddress for reprint requests and other correspondence: N. Paolocci, Ross 858, Div. of Cardiology, Johns Hopkins School of Medicine, 720 Rutland Ave., Baltimore, MD 21205 (e-mail: npaoloc1@jhmi.edu) Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationREFERENCES1 Adak S, Wang Q, Stuehr DJ. Arginine conversion to nitroxide by tetrahydrobiopterin-free neuronal nitric-oxide synthase. Implications for mechanism. J Biol Chem 275: 33554–33561, 2000.Crossref | PubMed | ISI | Google Scholar2 Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, Kemp-Harper B. A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. Br J Pharmacol. In press.Google Scholar3 Angeli A, Angelico F. Reactions of nitroxyl [NOH]. J Chem Soc Abstr 80: I, 322, 1901.Google Scholar4 Arnelle DR, Stamler JS. NO+, NO, and NO− donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch Biochem Biophys 318: 279–285, 1995.Crossref | PubMed | ISI | Google Scholar5 Bermejo E, Saenz DA, Alberto F, Rosenstein RE, Bari SE, Lazzari MA. Effect of nitroxyl on human platelets function. Thromb Haemost 94: 578–584, 2005.Crossref | PubMed | ISI | Google Scholar6 Cheong E, Tumbev V, Abramson J, Salama G, Stoyanovsky DA. Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium 37: 87–96, 2005.Crossref | PubMed | ISI | Google Scholar7 Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO 3rd, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 9: 1498–1505, 2003.Crossref | PubMed | ISI | Google Scholar8 Dai T, Tian Y, Tocchetti CG, Katori T, Murphy AM, Kass DA, Paolocci N, Gao WD. Nitroxyl increases force development in rat cardiac muscle. J Physiol 580: 951–960, 2007.Crossref | PubMed | ISI | Google Scholar9 Dierks EA, Burstyn JN. Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. Biochem Pharmacol 51: 1593–1600, 1996.Crossref | PubMed | ISI | Google Scholar10 Dobmeier KP, Riccio DA, Schoenfisch MH. Xerogel optical sensor films for quantitative detection of nitroxyl. Anal Chem 80: 1247–1254, 2008.Crossref | PubMed | ISI | Google Scholar11 Donzelli S, Espey MG, Flores-Santana W, Switzer CH, Yeh GC, Huang J, Stuehr DJ, King SB, Miranda KM, Wink DA. Generation of nitroxyl by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-l-arginine. Free Radic Biol Med 45: 578–584, 2008.Crossref | PubMed | ISI | Google Scholar12 Donzelli S, Espey MG, Thomas DD, Mancardi D, Tocchetti CG, Ridnour LA, Paolocci N, King SB, Miranda KM, Lazzarino G, Fukuto JM, Wink DA. Discriminating formation of HNO from other reactive nitrogen oxide species. Free Radic Biol Med 40: 1056–1066, 2006.Crossref | PubMed | ISI | Google Scholar13 Ellis A, Li CG, Rand MJ. Differential actions of l-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta. Br J Pharmacol 129: 315–322, 2000.Crossref | PubMed | ISI | Google Scholar14 Farmer PJ, Sulc F. Coordination chemistry of the HNO ligand with hemes and synthetic coordination complexes. J Inorg Biochem 99: 166–184, 2005.Crossref | PubMed | ISI | Google Scholar15 Favaloro JL, Kemp-Harper BK. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc Res 73: 587–596, 2007.Crossref | PubMed | ISI | Google Scholar16 Favaloro JL, Kemp-Harper BK. Redox variants of nitric oxide (NO· and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms. Am J Physiol Heart Circ Physiol; doi://10.1152/ajpheart.00008.2009.Google Scholar17 Fontani M, Costa M. Angelo Angeli, lo Scienziato Timido. Pisa, Italy: Riunione Scientifica della Societa' Chimica Italiana, 2004, p. 10–11.Google Scholar18 Froehlich JP, Mahaney JE, Keceli G, Pavlos CM, Goldstein R, Redwood AJ, Sumbilla C, Lee DI, Tocchetti CG, Kass DA, Paolocci N, Toscano JP. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry 47: 13150–13152, 2008.Crossref | PubMed | ISI | Google Scholar19 Fukuto JM, Chiang K, Hszieh R, Wong P, Chaudhuri G. The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 263: 546–551, 1992.PubMed | ISI | Google Scholar20 Fukuto JM, Jackson MI, Kaludercic N, Paolocci N. Examining nitroxyl in biological systems. Methods Enzymol 440: 411–431, 2008.Crossref | PubMed | ISI | Google Scholar21 Hoffman MD, Walsh GM, Rogalski JC, Kast J. Identification of nitroxyl-induced modifications in human platelet proteins using a novel mass spectrometric detection method. Mol Cell Proteomics. In press.Google Scholar22 Irvine JC, Favaloro JL, Kemp-Harper BK. NO− activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 41: 1301–1307, 2003.Crossref | PubMed | ISI | Google Scholar23 Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 49: 885–892, 2007.Crossref | PubMed | ISI | Google Scholar24 Katori T, Donzelli S, Tocchetti CG, Miranda KM, Cormaci G, Thomas DD, Ketner EA, Lee MJ, Mancardi D, Wink DA, Kass DA, Paolocci N. Peroxynitrite and myocardial contractility: in vivo versus in vitro effects. Free Radic Biol Med 41: 1606–1618, 2006.Crossref | PubMed | ISI | Google Scholar25 Katori T, Hoover DB, Ardell JL, Helm RH, Belardi DF, Tocchetti CG, Forfia PR, Kass DA, Paolocci N. Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ Res 96: 234–243, 2005.Crossref | PubMed | ISI | Google Scholar26 Miranda KM, Dutton AS, Ridnour LA, Foreman CA, Ford E, Paolocci N, Katori T, Tocchetti CG, Mancardi D, Thomas DD, Espey MG, Houk KN, Fukuto JM, Wink DA. Mechanism of aerobic decomposition of Angeli's salt (sodium trioxodinitrate) at physiological pH. J Am Chem Soc 127: 722–731, 2005.Crossref | PubMed | ISI | Google Scholar27 Miranda KM, Katori T, Torres de Holding CL, Thomas L, Ridnour LA, McLendon WJ, Cologna SM, Dutton AS, Champion HC, Mancardi D, Tocchetti CG, Saavedra JE, Keefer LK, Houk KN, Fukuto JM, Kass DA, Paolocci N, Wink DA. Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in Vivo. J Med Chem 48: 8220–8228, 2005.Crossref | PubMed | ISI | Google Scholar28 Miranda KM, Paolocci N, Katori T, Thomas DD, Ford E, Bartberger MD, Espey MG, Kass DA, Feelisch M, Fukuto JM, Wink DA. A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci USA 100: 9196–9201, 2003.Crossref | PubMed | ISI | Google Scholar29 Miranda KM, Yamada K, Espey MG, Thomas DD, DeGraff W, Mitchell JB, Krishna MC, Colton CA, Wink DA. Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys 401: 134–144, 2002.Crossref | PubMed | ISI | Google Scholar30 Mistry DK, Garland CJ. Nitric oxide (NO)-induced activation of large conductance Ca2+-dependent K+ channels (BKCa) in smooth muscle cells isolated from the rat mesenteric artery. Br J Pharmacol 124: 1131–1140, 1998.Crossref | PubMed | ISI | Google Scholar31 Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 97: 618–628, 2005.Crossref | PubMed | ISI | Google Scholar32 Pagliaro P, Mancardi D, Rastaldo R, Penna C, Gattullo D, Miranda KM, Feelisch M, Wink DA, Kass DA, Paolocci N. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med 34: 33–43, 2003.Crossref | PubMed | ISI | Google Scholar33 Paolocci N, Jackson MI, Lopez BE, Miranda K, Tocchetti CG, Wink DA, Hobbs AJ, Fukuto JM. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther 113: 442–458, 2007.Crossref | PubMed | ISI | Google Scholar34 Paolocci N, Katori T, Champion HC, St John ME, Miranda KM, Fukuto JM, Wink DA, Kass DA. Positive inotropic and lusitropic effects of HNO/NO− in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci USA 100: 5537–5542, 2003.Crossref | PubMed | ISI | Google Scholar35 Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, Espey MG, Fukuto JM, Feelisch M, Wink DA, Kass DA. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA 98: 10463–10468, 2001.Crossref | PubMed | ISI | Google Scholar36 Pino RZ, Feelisch M. Bioassay discrimination between nitric oxide (NO·) and nitroxyl (NO−) using l-cysteine. Biochem Biophys Res Commun 201: 54–62, 1994.Crossref | PubMed | ISI | Google Scholar37 Saleem M, Ohshima H. Xanthine oxidase converts nitric oxide to nitroxyl that inactivates the enzyme. Biochem Biophys Res Commun 315: 455–462, 2004.Crossref | PubMed | ISI | Google Scholar38 Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, Wilson GM, Di BG, O'Rourke B, Gao WD, Wink DA, Toscano JP, Zaccolo M, Bers DM, Valdivia HH, Cheng H, Kass DA, Paolocci N. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res 100: 96–104, 2007.Crossref | PubMed | ISI | Google Scholar39 Ulich BL, Hollis JM, Snyder LE. Radio detection of nitroxyl (HNO)–1st interstellar NO bond. Astrophys J 217: L105–L108, 1977.Crossref | ISI | Google Scholar40 Wanstall JC, Jeffery TK, Gambino A, Lovren F, Triggle CR. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol 134: 463–472, 2001.Crossref | PubMed | ISI | Google Scholar41 Wink DA, Feelisch M, Fukuto J, Chistodoulou D, Jourd'heuil D, Grisham MB, Vodovotz Y, Cook JA, Krishna M, DeGraff WG, Kim S, Gamson J, Mitchell JB. The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO. Arch Biochem Biophys 351: 66–74, 1998.Crossref | PubMed | ISI | Google Scholar42 Wink DA, Miranda KM, Katori T, Mancardi D, Thomas DD, Ridnour L, Espey MG, Feelisch M, Colton CA, Fukuto JM, Pagliaro P, Kass DA, Paolocci N. Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: a novel redox paradigm. Am J Physiol Heart Circ Physiol 285: H2264–H2276, 2003.Link | ISI | Google Scholar43 Wolin MS. Reactive oxygen species and the control of vascular function. Am J Physiol Heart Circ Physiol 296: H539–H549, 2009.Link | ISI | Google Scholar44 Wong PS, Hyun J, Fukuto JM, Shirota FN, DeMaster EG, Shoeman DW, Nagasawa HT. Reaction between S-nitrosothiols and thiols: generation of nitroxyl (HNO) and subsequent chemistry. Biochemistry 37: 5362–5371, 1998.Crossref | PubMed | ISI | Google Scholar Cited ByConjugated Polymers in the Context of Energy‐Storage Applications27 January 2023When NO . Is not Enough: Chemical Systems, Advances and Challenges in the Development of NO . and HNO Donors for Old and Current Medical Issues26 August 2021 | European Journal of Inorganic Chemistry, Vol. 2021, No. 42Versatile Ratiometric Fluorescent Probe Based on the Two-Isophorone Fluorophore for Sensing Nitroxyl26 October 2021 | Industrial & Engineering Chemistry Research, Vol. 60, No. 44Fluorescent probes for the detection of nitroxyl (HNO)Free Radical Biology and Medicine, Vol. 128Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aortaEuropean Journal of Pharmacology, Vol. 814A kinetic study on the reactivity of azanone ( HNO ) toward its selected scavengers: Insight into its chemistry and detectionNitric Oxide, Vol. 69Introduction: A Bit of History and General Facts About Nitroxyl: From Interstellar Molecule to Biological GasotransmitterChemists in the Period of the Institute for Higher Practical Studies and Specialization (1859–1924)16 April 2016Studies on the Reaction of Reduced Vitamin B 12 Derivatives with the Nitrosyl ­Hydride (HNO) Donor Angeli's Salt: HNO Oxidizes the Transition‐Metal Center of Cob(I)alamin17 July 2015 | European Journal of Inorganic Chemistry, Vol. 2015, No. 23Nitroxyl (HNO) for Treatment of Acute Heart Failure1 July 2014 | Current Heart Failure Reports, Vol. 11, No. 3Peroxynitrite Biology3 May 2014Enzymatic generation of the NO/HNO-releasing IPA/NO anion at controlled rates in physiological media using β-galactosidaseNitric Oxide, Vol. 35Nitroxyl (HNO)Circulation: Heart Failure, Vol. 6, No. 6Nitroglycerine and sodium trioxodinitrateJournal of Cardiovascular Medicine, Vol. 14, No. 10Italian Chemists' Contributions to Named Reactions in Organic Synthesis: An Historical Perspective4 September 2013 | Molecules, Vol. 18, No. 9Aorta from angiotensin II hypertensive mice exhibit preserved nitroxyl anion mediated relaxation responsesPharmacological Research, Vol. 65, No. 1Regulation of Heart Function by Endogenous Gaseous Mediators—Crosstalk Between Nitric Oxide and Hydrogen SulfideAntioxidants & Redox Signaling, Vol. 14, No. 11The Specificity of Nitroxyl Chemistry Is Unique Among Nitrogen Oxides in Biological SystemsAntioxidants & Redox Signaling, Vol. 14, No. 9Nitroxyl in the Central Nervous SystemAntioxidants & Redox Signaling, Vol. 14, No. 9Nitroxyl (HNO) signalingFree Radical Biology and Medicine, Vol. 47, No. 9 More from this issue > Volume 296Issue 5May 2009Pages H1217-H1220 Copyright & PermissionsCopyright © 2009 the American Physiological Societyhttps://doi.org/10.1152/ajpheart.00243.2009PubMed19286958History Received 10 March 2009 Accepted 11 March 2009 Published online 1 May 2009 Published in print 1 May 2009 Metrics Downloaded 259 times 23 CITATIONS 23 Total citations 1 Recent citation 4.24 Field Citation Ratio 0.48 Relative Citation Ratio publications21supporting0mentioning14contrasting0Smart Citations210140Citing PublicationsSupportingMentioningContrastingView CitationsSee how this article has been cited at scite.aiscite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.